HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Thrombocytopenia chromosome breakage

Familial thrombocytopenia associated with platelet autoantibodies and chromosome breakage
Also Known As:
Helmerhorst Heaton Crossen syndrome; Thrombocytopenia 2; Thrombocytopenia, Autosomal Dominant, 2; Thrombocytopenia, autosomal dominant
Networked: 68 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Neutropenia
2. Bacteremia
3. Thrombocytopenia (Thrombopenia)
4. Leukopenia
5. Anemia

Experts

1. Lara, Primo N: 2 articles (11/2019 - 06/2010)
2. Alcheikh, Ahmad: 1 article (11/2022)
3. Lowe, Gillian: 1 article (11/2022)
4. Morgan, Neil V: 1 article (11/2022)
5. Rabbolini, David J: 1 article (11/2022)
6. Stevenson, William S: 1 article (11/2022)
7. Vyas, Hrushikesh: 1 article (11/2022)
8. Borrachero Garro, Cristina: 1 article (07/2022)
9. Domínguez Senín, Loreto: 1 article (07/2022)
10. Santos-Rubio, María Dolores: 1 article (07/2022)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Thrombocytopenia chromosome breakage:
1. Heparin (Liquaemin)FDA LinkGeneric
04/01/1984 - "Positive results (greater than 20% aggregation) occurred in (1) five of 14 patients with heparin-associated thrombocytopenia, (2) 0 of 16 consumptive thrombocytopenic controls not given heparin therapy, (3) one of 14 nonthrombocytopenic controls given heparin, and (4) one of 13 healthy controls, giving a sensitivity of 36% and specificities of 100%, 93%, and 92%, respectively. "
01/01/2020 - "To ascertain: 1) the frequency of thrombocytopenia and heparin-induced thrombocytopenia; 2) positive predictive value of the Pretest Probability Score in identifying heparin-induced thrombocytopenia; and 3) clinical outcome of heparin-induced thrombocytopenia in adult patients receiving venovenous- or venoarterial-extracorporeal membrane oxygenation, compared with cardiopulmonary bypass. "
04/01/1984 - "No study has evaluated the diagnostic usefulness of testing for this factor, and we tested for a heparin-dependent platelet-aggregating factor in sera from (1) 14 patients with heparin-associated thrombocytopenia, (2) 14 nonthrombocytopenic controls given heparin, (3) 16 patients with consumptive thrombocytopenic disorders not associated with heparin, and (4) 13 healthy laboratory personnel. "
04/15/2003 - "The diagnosis of HIT was accepted in the case of a platelet drop of 50% or more and either the demonstration of heparin-dependent antibodies or (when this search could not be performed) the combination of the following features: (1) the absence of any other obvious clinical explanation for thrombocytopenia, (2) the occurrence of thrombocytopenia at least 5 days after heparin start, and (3) either the normalization of the platelet count within 10 days after heparin discontinuation or the earlier patient's death due to an unexpected thromboembolic complication. "
05/01/1989 - "All patients had associated hypercoagulable states: heparin-induced thrombocytopenia (2 patients), congenital deficiency of protein C (1 patient), and antithrombin III deficiency (3 patients). "
2. pegfilgrastim (Neulasta)FDA Link
3. Oseltamivir (Tamiflu)FDA Link
4. Probenecid (Benemid)FDA LinkGeneric
5. Platelet Activating FactorIBA
6. 5' Untranslated Regions (5' UTR)IBA
7. Inosine Triphosphate (ITP)IBA
8. AntibodiesIBA
9. EnzymesIBA
10. Biomarkers (Surrogate Marker)IBA

Therapies and Procedures

1. Therapeutics
2. Splenectomy
3. Pancreaticoduodenectomy
4. Thrombolytic Therapy
5. Extracorporeal Membrane Oxygenation